Anúncio
Anúncio

TNXP

TNXP logo

Tonix Pharmaceuticals Holding Corp.

16.46
USD
Patrocinado
+0.85
+5.41%
02 de jan., 10:57 UTC -5
Abrir

Relatórios de Lucros TNXP

Rácio de surpresa positiva

TNXP separação 21 de 40 últimas estimativas.

53%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.94M
/
-$3.22
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-10.61%
/
-10.31%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+13.90%
/
-67.04%

Tonix Pharmaceuticals Holding Corp. earnings per share and revenue

On 10 de nov. de 2025, TNXP reported earnings of -3.59 USD per share (EPS) for Q3 25, beating the estimate of -3.65 USD, resulting in a 1.82% surprise. Revenue reached 3.29 milhão, compared to an expected 3.16 milhão, with a 4.05% difference. The market reacted with a +4.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -3.22 USD, with revenue projected to reach 2.94 milhão USD, implying an diminuir of -10.31% EPS, and diminuir of -10.61% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Tonix Pharmaceuticals Holding Corp. reported EPS of -$3.59, beating estimates by 1.82%, and revenue of $3.29M, 4.05% above expectations.
The stock price moved up 4.1%, changed from $16.84 before the earnings release to $17.53 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 5 analistas, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$3.22 and revenue of $2.94M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio